Search research articles
Contact Us
Filters
Showing results (21-30 of 235) with videos related to
Page
of 24
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 16, 2002
Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit
Andrei C Sposito, M John Chapman
Circulation
|
September 5, 2013
Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease
Bronwyn A Kingwell, M John Chapman
Journal of the American College of Cardiology
|
October 26, 2019
Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years
M John Chapman, Henry N Ginsberg
Atherosclerosis. Supplements
|
February 8, 2003
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
Alexandros D Tselepis, M John Chapman
Pharmacology & Therapeutics
|
June 30, 2022
Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid
M John Chapman, R Preston Mason
Pharmacology & Therapeutics
|
January 25, 2008
Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy
M John Chapman, Andrei C Sposito
Journal of the American College of Cardiology
|
April 19, 2023
Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon
M John Chapman, Chris J Packard
Clinical Chemistry
|
September 2, 2020
LDL Cholesterol: 'The Times They Are A-Changin'
M John Chapman, Philippe Giral, Patrice Therond
Circulation
|
October 22, 2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"
Philippe Giral, Dominique Simon, M John Chapman
Current Opinion in Lipidology
|
April 26, 2020
Remnant lipoproteins: are they equal to or more atherogenic than LDL?
Carlos A Aguilar Salinas, M John Chapman
Page
of 24
Search research articles
Search
Showing results (21-30 of 235) with videos related to
Sort By:
Page
of 24
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 16, 2002
Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit
Andrei C Sposito, M John Chapman
Circulation
|
September 5, 2013
Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease
Bronwyn A Kingwell, M John Chapman
Journal of the American College of Cardiology
|
October 26, 2019
Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years
M John Chapman, Henry N Ginsberg
Atherosclerosis. Supplements
|
February 8, 2003
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
Alexandros D Tselepis, M John Chapman
Pharmacology & Therapeutics
|
June 30, 2022
Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid
M John Chapman, R Preston Mason
Pharmacology & Therapeutics
|
January 25, 2008
Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy
M John Chapman, Andrei C Sposito
Journal of the American College of Cardiology
|
April 19, 2023
Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon
M John Chapman, Chris J Packard
Clinical Chemistry
|
September 2, 2020
LDL Cholesterol: 'The Times They Are A-Changin'
M John Chapman, Philippe Giral, Patrice Therond
Circulation
|
October 22, 2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"
Philippe Giral, Dominique Simon, M John Chapman
Current Opinion in Lipidology
|
April 26, 2020
Remnant lipoproteins: are they equal to or more atherogenic than LDL?
Carlos A Aguilar Salinas, M John Chapman
Page
of 24